A World Class Thrombolytic Drug At An Affordable Cost For The Masses

According to the WHO, amongst all non-communicable diseases, cardiovascular disease (CVD) is the major cause of death in both developed and developing countries. In the year 2008, nearly 17 million people died of CVD around the globe, representing 30% death amongst all non-communicable diseases worldwide. The major chunk of death coming from the lower income group, would cross 25 million by 2030.

The knowledge that Thrombotic disorders are caused due to the imbalance in homeostasis between clot formation and clot dissolution, has led to development of newer thrombolytic preparations. With the advent of recombinant technology, focus had been to develop new mutants and hybrid protein derivatives through genetic engineering, enhancing selectivity and effectiveness. EPYGEN Biotech in co-operation with CSIR-IMTECH, intends to produce Recombinant Streptokinase (rSK) drug substance at high expression / yield and purity levels, rendering this live saving protein to be produced affordably, for the unmet need in the regional market.

A world class Thrombolytic drug at an affordable cost for the masses…is the motto of the rSK Team at EPYGEN.